A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Severe Renal Impairment
- Severe Renal Impairment
- Healthy
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Merck Sharp & Dohme LLC
- Enrolment target
- 20
- Started
- 8 September 2026
- Main results due
- 1 February 2027
- Study sites
- 1
- Registry updated
- 23 September 2026
Can you take part?
- Ages 18 years to 80 years.
- Open to any sex.
- Healthy volunteers can take part.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: All participants: * Has a body mass index (BMI) ≥18.0 and ≤40.0 kg/m\^2 Participants with Severe Renal impairment (RI): * The participant has stable renal function as determined by historical measurements. Healthy volunteers: * Is medically healthy with no clinically significant medical history Exclusion Criteria: The main exclusion criteria include but are not limited to the following: Renal Impairment Participants: * History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. Healthy Matched Control Participants: * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Study sites(1)
Floridian Clinical Research, LLC ( Site 0001)
Miami Lakes, Florida, United States
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07734610. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me